Trump Media and Technology Group Corp vs Cassava Sciences Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.13 (market cap $2.28B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Trump Media and Technology Group Corp is far larger — about 57.9× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 3,148,379). Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Cassava Sciences Inc for 37 Days on average.
| DJT | FLNA | |
|---|---|---|
Market Cap | $2.28B | $39.40M |
Volume | 3,148,379 | 759,018 |
Sector | Media | Health |
52-Week High | $17.07 | $4.64 |
52-Week Low | $7.06 | $0.68 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $2.35B | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.125, down 1.16% with a bearish technical signal. The company shows minimal revenue of $3.68M against massive losses of -$712M, resulting in a negative net margin of -28,860%. Cash flow trends reveal heavy investing outflows, while a proposed merger with TAE Technologies aims to pivot toward fusion energy development. The stock faces significant fundamental challenges despite oversold RSI indicators.
Outlook remains highly speculative with substantial execution risks. The merger could provide long-term upside if fusion technology commercializes, but current financials and negative profitability signal extreme caution. Investors face dilution risk and cash burn with no near-term profit visibility.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →